| 23 Mai 2016
CentoMD®, the world’s  leading proprietary human genetic interpretation database, is based on  the knowledge created by our worldwide diagnostic testing services  incorporating unprecedented global diversity. By analyzing thousands of  genes across multi-cultural and ethnically diverse populations, CentoMD®  is an ever growing systematically annotated dataset of identified  variants correlated with clinical information and epidemiological data.  It provides clear statements on clinical significance. Data from more  than 74,000 diagnosed individuals and >22,000 genes are curated in  detail, and the clinical significance of these variants is evaluated  following strict guidelines and based on a sophisticated clinical Human  Phenotype Ontology (HPO) system. With the new release of  CentoMD® 3.0, the medical community now has access to an advanced  Phenotype-to-Genotype module that enables symptom-based queries and  returns candidate genes as well as associated variants underlying the  symptoms of interest. Vice versa, the Genotype-to-Phenotype module  provides an interactive search interface to select and filter through  genes, transcripts, variants. It enables users to access detailed  variant and individual-related data based on ~2.2 million classified  variants, including variants detected by whole exome sequencing. “Understanding the burden  of a disease to a patient, especially if it is a rare hereditary  disease, is the daily work of us physicians. Revealing the cause of a  disease will have an immediate impact on the patient. With CentoMD®, we  continuously enhance the interpretation of mutations with a remarkable  ratio of 56% not yet published clinical relevant variants and mutations.  Using all available information allows physicians to diagnose and treat  hereditary diseases in a much more efficient, speedy and targeted  manner,” stated Professor Arndt Rolfs, CEO of CENTOGENE.
(PresseBox)  CENTOGENE AG (“CENTOGENE”) announces the launch of the completely updated CentoMD® 3.0